SlovakiaTuberculosis profile
Population  2015 5.4 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.032 (0.031–0.032) 0.59 (0.58–0.59)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0 (0–0)
Incidence  (includes HIV+TB) 0.35 (0.3–0.41) 6.5 (5.6–7.5)
Incidence (HIV+TB only) 0 (0–0) 0.01 (0–0.01)
Incidence (MDR/RR-TB)** <0.01 (<0.01–<0.01) 0.02 (0.01–0.04)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.015 (0.01–0.019) 0.13 (0.091–0.16) 0.14 (0.1–0.18)
Males <0.01 (<0.01–0.012) 0.2 (0.16–0.25) 0.21 (0.16–0.26)
Total 0.024 (0.017–0.03) 0.33 (0.3–0.36) 0.35 (0.3–0.41)
TB case notifications, 2015  
Total cases notified 317
Total new and relapse 308
          - % tested with rapid diagnostics at time of diagnosis 22%
          - % with known HIV status  
          - % pulmonary 83%
          - % bacteriologically confirmed among pulmonary 66%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.09 (0.08–0.1)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 0  
          - on antiretroviral therapy 0  
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  1
(0–3)
Estimated % of TB cases with MDR/RR-TB 0% (0–2.6) 3.7% (0.09–19)  
% notified tested for rifampicin resistance <1% 15% 7
MDR/RR-TB cases tested for resistance to second-line drugs   7
Laboratory-confirmed cases MDR/RR-TB: 7, XDR-TB: 1
Patients started on treatment **** MDR/RR-TB: 2, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 88% 318
Previously treated cases, excluding relapse, registered in 2014 71% 14
HIV-positive TB cases, all types, registered in 2014   0
MDR/RR-TB cases started on second-line treatment in 2013 0% 2
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
100% (100–100)
TB financing, 2016  
National TB budget (US$ millions) <1
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-10 Data: www.who.int/tb/data